Errol P. Prens

Erasmus MC — Netherlands

Medicine · Health Sciences

66h-index19.6kcitations351works7.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hidradenitis Suppurativa and Treatments(167), Colorectal and Anal Carcinomas(141), Psoriasis: Treatment and Pathogenesis(68), Dermatology and Skin Diseases(48), Microscopic Colitis(46)

Publications350 total

Evaluating the Diagnostic Accuracy of a Screening Questionnaire for Detecting Hidradenitis Suppurativa: A Pooled Analysis of Accuracy Measures from the Global Hidradenitis Suppurativa Atlas (GHiSA) Study
British Journal of Dermatology·2026
085 Remibrutinib in patients with moderate to severe hidradenitis suppurativa: Patient reported outcomes from a randomized, phase 2, double-blind, placebo-controlled platform study
Journal of Investigative Dermatology·2025Open Access
322 The polygenic architecture of hidradenitis suppurativa defined in a cohort of 6,500 HS cases implicates misdirected keratinocyte migration in pathogenesis
Journal of Investigative Dermatology·2025
Bimekizumab impact on flare in hidradenitis suppurativa over 2 years: Data from BE HEARD EXT
SKIN The Journal of Cutaneous Medicine·2025Open Access
52 The polygenic architecture of hidradenitis suppurativa reveals clinically relevant epithelial signaling mechanisms
Journal of Investigative Dermatology·2025
40 Neutrophil Extracellular Traps in Hidradenitis Suppurativa Skin and Serum as Target for CIT-013, a Novel NET Inhibiting Therapy
Journal of Investigative Dermatology·2025
Bimekizumab Pain Outcomes in Patients with Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II Phase 3 Randomized Clinical Trials
Pain and Therapy·2025Open Access
Vilobelimab to improve clinical outcomes in moderate-to-severe hidradenitis suppurativa through an adjunctive effect on draining tunnels: results of the SHINE double-blind placebo-controlled randomized trial
British Journal of Dermatology·2025· 2 citedOpen Access
Metformin in conjunction with doxycycline is not superior to doxycycline monotherapy for hidradenitis suppurativa; results of a phase III double-blinded randomized placebo- controlled trial
British Journal of Dermatology·2025Open Access
62279 Remibrutinib in patients with moderate to severe hidradenitis suppurativa: Patient reported outcomes from a randomized, phase 2, double-blind, placebo-controlled platform study
Journal of the American Academy of Dermatology·2025· 3 cited
63286 Bimekizumab effect on pain severity and impact in moderate to severe hidradenitis suppurativa: 2-year results from BE HEARD EXT
Journal of the American Academy of Dermatology·2025
62305 IHS4-100 responses and other IHS4 outcomes with the IL-17A- and IL-17F-inhibiting Nanobody sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS): Week 24 results from the Phase 2 MIRA trial
Journal of the American Academy of Dermatology·2025
Prevalence of Hidradenitis Suppurativa
JAMA Dermatology·2025· 6 citedOpen Access
Establishment of standardized definitions and a core set of outcome characteristics following hidradenitis suppurativa surgery developed by an expert Delphi consensus
Journal of the American Academy of Dermatology·2025· 1 citedOpen Access
The polygenic architecture of hidradenitis suppurativa reveals signaling mechanisms that implicate epithelial remodeling
2025· 1 citedOpen Access
0564 Hidradenitis suppurativa GWAS identifies 12 loci that implicate misdirected keratinocyte migration in pathogenesis
Journal of Investigative Dermatology·2025
Prevalence of Hidradenitis Suppurativa in the Netherlands: A Cross-Sectional Study as Part of the Global Hidradenitis Suppurativa Atlas (GHiSA)
Dermatology·2025· 1 citedOpen Access
Prevalence of Hidradenitis Suppurativa in the Gulf Province of Papua New Guinea
Dermatology·2025· 1 citedOpen Access
Bimekizumab Impact on Flare in Hidradenitis Suppurativa Over 2 Years: Data from BE HEARD EXT
SKIN The Journal of Cutaneous Medicine·2025Open Access
Neutrophil Extracellular Traps Are Widely Distributed Across Lesional and Perilesional Hidradenitis Suppurativa Skin, and Elevated Serum <scp>NET</scp> Markers Associate With Moderate to Severe <scp>HS</scp> Disease
International Journal of Dermatology·2025· 6 citedOpen Access
page 1 of 18Next →

Frequent Co-authors

Hessel H. van der Zee(23), Gregor B. E. Jemec(17), Jurr Boer(13), Christos C. Zouboulis(12), Jacek C. Szepietowski(8), Jon D. Laman(7), Alexa B. Kimball(7), Inge E. Deckers(7), Łukasz Matusiak(6), Thrasyvoulos Tzellos(6), Barbara Horváth(6), Falk G. Bechara(5), Evangelos J. Giamarellos‐Bourboulis(5), V. del Mármol(5), Lennart Emtestam(4), Robert E. Hunger(4), John R Ingram(4), Joslyn S. Kirby(4), Allard R.J.V. Vossen(4), Leslie van der Fits(3)